Lee T. Bacheler

Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors

Patrick Y. S. Lam, Prabhakar K. Jadhav, Charles J. Eyermann et al. · Science · 1994 · 836 citations

Pharmacy, Medicinal Chemistry, Pharmacology +16

Inhibition of Clinically Relevant Mutant Variants of HIV-1 by Quinazolinone Non-Nucleoside Reverse Transcriptase Inhibitors

Jeffrey W. Corbett, Soo S. Ko, James D. Rodgers et al. · Journal of Medicinal Chemistry · 2000 · 301 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy

Lee T. Bacheler, Elizabeth D. Anton, Phil Kudish et al. · Antimicrobial Agents and Chemotherapy · 2000 · 270 citations

Life Sciences, Infectious Diseases, Molecular Genetics +17

Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence

Matthew C. Strain, Huldrych F. Günthard, Diane V. Havlir et al. · Proceedings of the National Academy of Sciences · 2003 · 250 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy

Lee T. Bacheler, Susan Jeffrey, George J. Hanna et al. · Journal of Virology · 2001 · 240 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17